PharmaTher's Sairiyo Therapeutics to Explore PD-001, Its Patented Reformulated Cepharanthine, for Hantavirus
PharmaDrug Sairiyo Therapeutics to Explore PD-001, Its Patented Reformulated Cepharanthine, for Hantavirus
PharmaDrug Completes Acquisition of Initial 19.9% Interest in Canurta Inc. and Completes Debt Restructuring
PharmaDrug Announces Debt Restructuring
PharmaDrug Signs Definitive Agreement to Acquire Equity Interest in Canurta Inc
PharmaDrug Inc.: Correction to News Release Dated July 30, 2025
PharmaDrug Signs LOI to Acquire Equity Interest in Canurta Inc.
PharmaDrug Announces Resignation of Rob Steen as CEO and From Board of Directors
PharmaDrug Announces Strategic Review Process Intended to Maximize Shareholder Value
PharmaDrug Announces Issuance of Debenture Units
PharmaDrug Announces Proposed Issuance of Debenture Units
PharmaDrug's Sairiyo Therapeutics Announces Successful Completion of Stability Study of PD-001 (Patented Reformulated Cepharanthine) to Support Use in Phase 1 Study for Viral Infectious Diseases
PharmaDrug's Sairiyo Therapuetics Announces Initiation of Study Start-Up Activities and Design for Clinical Trial of PD-001 (Patented Reformulated Cepharanthine) for Viral Infectious Diseases
PharmaDrug's Sairiyo Therapuetics Provides Strategic Plans to Advance PD-001 (Patented Reformulated Cepharanthine) for Viral Infectious Diseases
PharmaDrug's Sairiyo Therapuetics Announces Independent Screening Identifying Cepharanthine's Potential to Bind to Monkeypox (Mpox) Proteins
PharmaDrug's Sairiyo Therapuetics Receives Approval to Initiate Phase 1 Clinical Trial of Patented Reformulated Cepharanthine
PharmaDrug's Sairiyo Therapeutics Submits Clinical Trial Application for Phase 1 Study of Patented Reformulated Cepharanthine
PharmaDrug Announces Director Appointment and Resignation
PharmaDrug's Sairiyo Therapeutics Completes Clinical and Regulatory Package for Phase 1 Study of Patented Reformulated Cepharanthine
PharmaDrug Appoints Current Board Member Dr. David Kideckel as Chairman
PharmaDrug's Sairiyo Therapeutics pursuing in-human study of PD-001 in Australia following manufacturing milestone
PharmaDrug's Sairiyo Successfully Demonstrates Ability to Manufacture Cepharanthine (PD-001) for Human Clinical Studies
PharmaDrug Inc. Engages Investor Relations and Marketing Service Providers
PharmaDrug Inc. Announces Successful Closing of Non-Brokered Private Placement
PharmaDrug Inc. Announces Proposed Non-Brokered Private Placement
PharmaDrug to continue Securedose Synthetics' R&D activities following acquisition
PharmaDrug Inc. Announces Grant of Stock Options
PharmaDrug closes Securedose Synthetics acquisition
PharmaDrug Inc. Closes Acqusition of Securedose Synthetics
PharmaDrug to acquire Securedose Synthetics in all-stock deal
PharmaDrug Inc. Enters Definitive Agreement to Acquire SecureDose Synthetics
PharmaDrug to consolidate shares, appoints new CFO
PharmaDrug consolidates shares, appoints new CFO
PharmaDrug Announces Share Consolidation and Change to Chief Financial Officer
PharmaDrug Announces Amendment to Shareholder Meeting Matter
PharmaDrug advances investigational cancer therapeutic PD-001 toward in human safety trials
PharmaDrug Provides Development Update of Cepharanthine (PD-001) for Cancer and Infectious Disease
PharmaDrug appoints Robert Steen as CEO and chairman
PharmaDrug Announces Appointment of CEO and Changes to the Board of Directors
PharmaDrug announces $300,000 strategic investment in Sairiyo subsidiary by PharmaTher
PharmaDrug Announces Strategic Investment in Sairiyo Therapeutics Inc.
PharmaDrug brings on veteran consultant to maximize cepharanthine and DMT program value
PharmaDrug partners with PharmaTher to develop DMT transdermal patch technology
PharmaDrug unveils plans for first-in-human clinical study with its lead drug candidate PD-001 in esophageal cancer
PharmaDrug files patent cooperation treaty for PD-001 as treatment for prostate cancer, opening window for protection in 153 countries
PharmaDrug wraps up key step in production of oral bioavailable version of its oncology and infectious disease drug cepharanthine
PharmaDrug aims to file provisional patent for treatment of glaucoma in the fourth quarter this year
PharmaDrug completes significant groundwork to support multi-kilogram production of cepharanthine-2HCL drug
PharmaDrug closes sale of German cannabis assets to Khiron Life Sciences
PharmaDrug announces non-brokered offering of $650,000 of convertible secured debentures and issuance of shares